---
title: "Machine-learning adaptive forecasts for antiretroviral therapy demand in India’s national HIV prog"
id: "medrxiv-22-adaptive-forecasting-of-antiretroviral-therapy-demand-using-machine-learning-in"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-22-adaptive-forecasting-of-antiretroviral-therapy-demand-using-machine-learning-in"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.25.26361170v1?rss=1"
published_at: "2026-08-28T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Machine-learning adaptive forecasts for antiretroviral therapy demand in India’s national HIV prog
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-22-adaptive-forecasting-of-antiretroviral-therapy-demand-using-machine-learning-in
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.25.26361170v1?rss=1)
- **Published At:** 2026-08-28T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- India’s National AIDS Control Organization (NACO) oversees one of the world’s largest public **antiretroviral therapy (ART)** programmes, where stock-outs harm viral suppression and can drive resistance. - The study developed an end-to-end, regimen-specific forecasting workflow to support procurement during periods of unstable demand caused by regimen transitions, formulation changes, guideline updates, and procurement-driven consumption shifts. - Monthly national ART consumption data from January 2013 through December 2024 were analyzed; pipeline development used a privacy-preserving synthetic dataset and final evaluation used real national consumption series (real data available only to February 2024). - Five models across three classes were compared: classical (Holt-Winters, ARIMA), transformer-based (TimesFM and a log-transformed TimesFM), and hybrid ARIMA–TimesFM residual variants. - Forecast horizon was fixed at 18 months; training/test splits differed between synthetic and real-data evaluations because of data availability. - Forecast accuracy was measured using signed percentage deviation (SPD) to retain directionality (positive = under-prediction; negative = over-prediction); models were selected by smallest absolute deviation. - A regimen-specific model-error buffer was derived and applied only to under-predictions; the workflow was deployed through a no-code dashboard for decision support. - Performance varied by regimen: on synthetic data absolute deviations ranged from 0.46% (adult ABC+3TC) to 11.92% (adult AZT+3TC). On real data, classical methods were competitive for some series while transformer and hybrid models outperformed others. - Example real-data results: for adult AZT+3TC a Hybrid 70th percentile model yielded SPD −2.02% while other models ranged −15.7 to 8.87; for adult Ritonavir an ARIMA–TimesFM hybrid at the 30th percentile yielded SPD −5.2% versus a range of −14.94 to 17.25 for other models. - Low-volume and transition regimens, especially pediatric formulations, remained hard to forecast. All models systematically erred in the same direction for pediatric regimens: pediatric ABC+3TC over-predicted (range −82.74 to −67.43), while pediatric AZT+3TC and LPV/r 125 mg under-predicted (ranges 24.93 to 63.73 and 18.32 to 52.07, respectively). - The authors recommend a portfolio approach—regimen-specific model selection, directional error reporting, and cautious buffering—rather than replacing established procurement systems, and note the study is a preprint not yet peer-reviewed.
## Clinical Analysis & Structured Key Points
Adaptive forecasting of antiretroviral therapy demand using machine learning in India's national HIV programme | medRxiv Skip to main content Adaptive forecasting of antiretroviral therapy demand using machine learning in India's national HIV programme View ORCID Profile Muskaan Chugh , View ORCID Profile Bhavesh Neekhra , Manish Bamrotiya , View ORCID Profile Steven J Clipman , View ORCID Profile Debayan Gupta doi: https://doi.org/10.64898/2026.08.25.26361170 Muskaan Chugh 1 Department of Computer Science, Ashoka University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Muskaan Chugh Bhavesh Neekhra 1 Department of Computer Science, Ashoka University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Bhavesh Neekhra Manish Bamrotiya 2 Johns Hopkins University School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Steven J Clipman 2 Johns Hopkins University School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Steven J Clipman Debayan Gupta 1 Department of Computer Science, Ashoka University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Debayan Gupta For correspondence: debayan.gupta{at}ashoka.edu.in Abstract Info/History Metrics Data/Code Preview PDF Abstract Antiretroviral therapy (ART) stock-outs interrupt treatment, increase the risk of virologic failure and drug resistance, and erode the population-level benefits of viral suppression. India's National AIDS Control Organization (NACO) manages one of the world's largest public ART programmes, where regimen transitions, evolving formulations, changing treatment guidelines, and procurement-driven fluctuations in drug consumption complicate forecasting. We developed an end-to-end, regimen-specific forecasting workflow to support procurement planning during such periods of instability. We analyzed monthly national ART consumption data from January 2013 through December 2024. A privacy-preserving synthetic dataset was used for pipeline development, followed by final evaluation on real national consumption time series. We compared three model classes, comprising five models: (1) classical models (Holt-Winters and ARIMA), (2) transformer models (TimesFM, which is a large pre-trained time-series foundation model, and its variant with logarithmically transformed values), and (3) hybrid models (variants of a hybrid ARIMA-TimesFM residual model). While the forecast horizon of 18 months remained constant, the train-test period varied across real and synthetic data, as real data was only available until February 2024. For synthetic data, models were trained through June 2023 (test window was July 2023-December 2024), while for real data, models were trained through August 2022 (our test window was September 2022-February 2024). We reported signed percentage deviation to preserve whether models tended to over-or under-predict, and selected models by the smallest absolute deviation. We then derived a regimen-specific model-error buffer, applied only to held-out under-prediction, and deployed the workflow through a no-code dashboard. Forecasting performance was determined using signed percentage deviation (SPD), wherein positive change represents under-prediction and negative change represents over-prediction. Performance varied across regimens, indicating that no single approach was best-performing for all formulations. On synthetic benchmark data, the smallest absolute deviations ranged from 0.46% for adult ABC+3TC to 11.92% for adult AZT+3TC. On real consumption data, classical methods remained competitive for some series, whereas transformer and hybrid models produced better predictive outcomes for others. For instance, for adult AZT+3TC, the Hybrid 70th percentile achieved an SPD of -2.02%, in contrast to the error range of [-15.7, 8.87] for other models. For adult Ritonavir, the ARIMA-TimesFM hybrid at the 30th percentile achieved an SPD of -5.2%, in contrast to the error range of [-14.94, 17.25] for other models. Several formulations, particularly low-volume and transition regimens, nevertheless remained difficult to forecast accurately, underscoring persistent operational uncertainty. This was especially evident across the three pediatric regimens, where all models deviated systematically in the same direction - a more concerning pattern than mere magnitude. For pediatric ABC+3TC, all models over-predicted within a narrow band of [-82.74, -67.43], while for pediatric AZT+3TC and LPV/r 125 mg, all models under-predicted, with ranges of [24.93, 63.73] and [18.32, 52.07] respectively. These findings support a portfolio approach to forecasting in national HIV programmes. Rather than replacing established public-health procurement systems, regimen-specific model selection, directional error reporting, and cautious model-error buffering can strengthen decision support during regimen transitions and other periods of unstable demand. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This was a secondary analysis of de-identified data, and Johns Hopkins issued a Not Human Subjects Research determination (IRB00446614). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The real data underlying this study are national aggregate ART consumption records provided by India's National AIDS Control Organization under a data-use agreement and are not publicly available. A validated synthetic dataset, the full analysis code, and dashboard source code are available on Zenodo at DOI: 10.5281/zenodo.21839042. https://doi.org/10.5281/zenodo.21839042 Funder Information Declared Johns Hopkins Gupta-Klinsky India Institute , GK 80064639 National Institutes of Health , DP2DA056130 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Back to top Previous Next Posted August 28, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Adaptive forecasting of antiretroviral therapy demand using machine learning in India's national HIV programme Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Adaptive forecasting of antiretroviral therapy demand using machine learning in India's national HIV programme Muskaan Chugh , Bhavesh Neekhra , Manish Bamrotiya , Steven J Clipman , Debayan Gupta medRxiv 2026.08.25.26361170; doi: https://doi.org/10.64898/2026.08.25.26361170 Share This Article: Copy Citation Tools Adaptive forecasting of antiretroviral therapy demand using machine learning in India's national HIV programme Muskaan Chugh , Bhavesh Neekhra , Manish Bamrotiya , Steven J Clipman , Debayan Gupta medRxiv 2026.08.25.26361170; doi: https://doi.org/10.64898/2026.08.25.26361170 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area HIV/AIDS Subject Areas All Articles Addiction Medicine (612) Allergy and Immunology (893) Anesthesia (325) Cardiovascular Medicine (4754) Dentistry and Oral Medicine (474) Dermatology (406) Emergency Medicine (640) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1610) Epidemiology (15806) Forensic Medicine (32) Gastroenterology (1194) Genetic and Genomic Medicine (6970) Geriatric Medicine (726) Health Economics (1051) Health Informatics (4960) Health Policy (1422) Health Systems and Quality Improvement (1731) Hematology (578) HIV/AIDS (1329) Infectious Diseases (except HIV/AIDS) (16229) Intensive Care and Critical Care Medicine (1158) Medical Education (661) Medical Ethics (150) Nephrology (718) Neurology (7164) Nursing (361) Nutrition (1072) Obstetrics and Gynecology (1226) Occupational and Environmental Health (999) Oncology (3563) Ophthalmology (1032) Orthopedics (392) Otolaryngology (445) Pain Medicine (464) Palliative Medicine (139) Pathology (702) Pediatrics (1771) Pharmacology and Therapeutics (730) Primary Care Research (758) Psychiatry and Clinical Psychology (5816) Public and Global Health (9666) Radiology and Imaging (2372) Rehabilitation Medicine and Physical Therapy (1428) Respiratory Medicine (1238) Rheumatology (632) Sexual and Reproductive Health (762) Sports Medicine (572) Surgery (763) Toxicology (106) Transplantation (301) Urology (285)
## Related Clinical Research

- [Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-case-report-of-admio-type-1-caused-by-a-de-novo-stat3-gain-of-function.md)
- [Predictors of Healthcare Costs for Commercially Insured Adults with Tuberculosis in the US (2013–2](https://medichelpline.com/clinical-feed/medrxiv-0-predictors-of-healthcare-costs-among-commercially-insured-persons-with.md)
- [Immediate versus delayed antiretroviral therapy in Japan: cost-effectiveness and budget impact](https://medichelpline.com/clinical-feed/medrxiv-6-treating-earlier-spending-less-cost-effectiveness-and-budget-impact-of.md)
- [COVID-19 and Reactivation of Epstein-Barr, Herpes, and Anelloviridae: Study Findings](https://medichelpline.com/clinical-feed/medical-news-today-0-covid-19-may-reactivate-epstein-barr-herpes-viruses-what-this-means.md)
- [FDA approves Moderna’s mRNA flu vaccine mFLUSIVA for adults 50+: what clinicians should know](https://medichelpline.com/clinical-feed/medical-news-today-0-moderna-s-mrna-flu-vaccine-approved-by-fda-when-is-it-available.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.